ESC 2023 Acute Coronary Syndromes (ACS) Guidelines – STEMI, NSTEMI, and Unstable Angina

Abstract

The 2023 ESC Acute Coronary Syndromes guidelines introduce a streamlined, risk-driven framework for diagnosing and managing STEMI, NSTEMI, and unstable angina. 

Central updates include refined high-sensitivity troponin pathways, reinforced use of the GRACE 2.0 score, and a more prescriptive approach to early invasive evaluation based on objective risk tiers. Antiplatelet therapy guidance emphasises personalised dual antiplatelet therapy duration, the preferential use of potent P2Y12 inhibitors, and tailored regimens for patients with a high bleeding risk. STEMI management prioritises timely primary PCI, while NSTEMI care incorporates clear distinctions between immediate, early, and selective invasive strategies. 

Collectively, these updates aim to reduce treatment delays, optimise antithrombotic safety, and strengthen precision-based decision-making across diverse ACS populations.

Introduction

Acute coronary syndromes (ACS) remain a leading global cause of morbidity, mortality, and healthcare utilisation. The 2023 ESC guidelines introduce an evidence-driven framework that prioritises faster diagnostic confirmation, earlier risk stratification, and individualised antithrombotic and invasive management strategies. 

Advances in high-sensitivity cardiac troponin testing, expanded validation of the GRACE 2.0 score, and updated recommendations for dual antiplatelet therapy collectively shift clinical decision-making toward greater precision and safety. Clear delineation between STEMI, NSTEMI, and unstable angina is anchored in refined diagnostic thresholds and structured timelines for reperfusion or invasive evaluation.

The overarching objective is to support timely, standardised, and patient-specific ACS care aligned with contemporary evidence, ultimately reducing preventable cardiovascular events.

Pathophysiology and Clinical Spectrum of ACS

ACS results from a sudden reduction in coronary blood flow, most commonly triggered by the disruption of atherosclerotic plaque. 

Plaque rupture exposes thrombogenic necrotic material, leading to platelet aggregation and fibrin-rich thrombus formation. Plaque erosion, more common in younger patients and women, involves endothelial denudation without cap rupture, producing platelet-rich thrombi. Less common mechanisms include spontaneous coronary artery dissection, coronary embolism, and microvascular dysfunction.

The clinical spectrum — STEMI, NSTEMI, and unstable angina—represents a continuum of ischemic severity. STEMI is caused by complete or near-complete occlusion, leading to transmural ischemia and ST-segment elevation. NSTEMI reflects partial or dynamic obstruction with subendocardial necrosis and elevated troponin. Unstable angina shares ischemic mechanisms but lacks biomarker elevation. 

Recognising these distinctions, alongside atypical presentations and MINOCA, is critical for targeted diagnostic and therapeutic strategies.

Diagnosis and Risk Stratification

Timely diagnosis relies on integrating clinical presentation, ECG, and high-sensitivity cardiac troponin testing. Accelerated 0/1-hour or 0/2-hour algorithms enable rapid rule-in or rule-out, reducing unnecessary admissions while maintaining high sensitivity. ECG remains essential for STEMI recognition; repeated tracings and echocardiography clarify ambiguous cases, while coronary CT angiography serves as a noninvasive alternative in selected patients.

Risk stratification is mandatory prior to invasive decision-making. GRACE 2.0 is recommended to estimate short-term mortality and guide the timing of intervention. High GRACE scores, hemodynamic instability, refractory symptoms, arrhythmias, or dynamic ST-T changes signal the need for expedited invasive evaluation. 

TIMI scoring may aid secondary risk assessment, but, is not a substitute for GRACE in determining invasive timing.

Management of STEMI

Restoring coronary perfusion rapidly is the cornerstone of STEMI management. Primary PCI is preferred, with door-to-balloon times aligned to guideline targets. When PCI is delayed beyond recommended windows, fibrinolytic therapy is indicated, followed by routine angiography. Failed thrombolysis requires immediate rescue PCI.

Antiplatelet therapy includes aspirin plus a potent P2Y12 inhibitor (prasugrel or ticagrelor), with clopidogrel reserved for contraindications or high bleeding risk. Dual antiplatelet therapy duration is individualised. Parenteral anticoagulation during PCI employs unfractionated heparin, with enoxaparin or bivalirudin as alternatives.

Adjunctive therapies—early beta-blockers, high-intensity statins, ACE inhibitors or ARBs, and mineralocorticoid receptor antagonists—support long-term cardiovascular protection. Structured transitions of care, including cardiac rehabilitation and secondary prevention optimisation, remain essential to reduce recurrent events.

Management of NSTEMI and Unstable Angina

NSTEMI and unstable angina require risk-adjusted management. High-risk patients (e.g., hemodynamic compromise, arrhythmias, refractory angina, dynamic ST changes) need immediate invasive assessment. Intermediate-risk patients benefit from early (<24 hours) angiography, while low-risk patients may follow selective invasive strategies.

Antiplatelet therapy is initiated at diagnosis with potent P2Y12 inhibitors in eligible patients; aspirin remains foundational. Anticoagulation during the acute phase includes unfractionated heparin, enoxaparin, or fondaparinux, tailored to procedural plans and renal function. Routine pretreatment with P2Y12 inhibitors is individualised.

Optimal medical therapy includes beta-blockers, ACE inhibitors/ARBs, high-intensity statins, and mineralocorticoid receptor antagonists. 

In unstable angina, focus is on ischemic symptom control and prevention of progression to infarction. DAPT duration should balance ischemic and bleeding risk, with comorbidities (CKD, diabetes, frailty) influencing therapy selection.

Special Populations

Management adjustments are essential in elderly, frail, CKD, diabetic, and atypical presentation populations.

• Elderly/Frail: Dose modifications, shortened DAPT, and careful invasive selection. Shared decision-making is critical.
  
  
• CKD: Adjust anticoagulation, minimise contrast, and monitor for bleeding; biomarker interpretation requires context.
  
  
• Diabetes: Early invasive strategy, aggressive secondary prevention, potent antiplatelet therapy while monitoring for bleeding and metabolic control.
  
  
• Women/Atypical Presentations: Increased vigilance due to subtle symptoms, non-obstructive disease prevalence, and microvascular dysfunction.
  
  
• Atrial Fibrillation: Minimise triple therapy duration; early transition to dual therapy with anticoagulant and single antiplatelet agent.
  
  

Across populations, individualised therapy balances ischemic and bleeding risk, optimising outcomes.

Emerging Therapies and Research Directions

• Precision Antiplatelet Therapy: Genotype-guided P2Y12 selection and ultra-short DAPT followed by monotherapy under study.
  
  
• Novel Antithrombotic Agents: Factor XIa inhibitors and targeted anticoagulants offer potential for reduced bleeding.
  
  
• Advanced Biomarkers: Multi-marker panels for plaque instability, microvascular dysfunction, and inflammation may improve diagnosis and risk stratification.
  
  
• AI Applications: Machine learning for ECG, imaging, and outcome prediction may enhance clinical decision-making.
  
  
• PCI Innovations: Intravascular imaging, thin-strut stents, physiology-guided stenting, and hybrid strategies improve procedural outcomes.
  
  

While not yet guideline-endorsed, these developments represent the next frontier in personalised ACS care.

Clinical Practice Summary / Key Takeaways

1. Diagnosis: Use high-sensitivity troponin with 0/1 or 0/2-hour algorithms; confirm with ECG, echo, or CT as needed.
   
   
2. STEMI: Primary PCI preferred; DAPT with aspirin plus potent P2Y12 inhibitor; early initiation of adjunctive therapy.
   
   
3. NSTEMI/Unstable Angina: Risk-stratified invasive strategy; tailored DAPT and anticoagulation; comorbidity-adjusted therapy.
   
   
4. Special Populations: Adjust dosing, duration, and invasive strategies for elderly, frail, CKD, diabetic, and female patients.
   
   
5. Emerging Approaches: Precision antiplatelet therapy, AI, advanced biomarkers, and novel anticoagulants are under investigation.
   
   
6. Principle: Evidence-based, risk-adjusted, patient-centred care balancing ischemic protection with bleeding risk.